EyePoint Pharmaceuticals (United States)
- Research works
- 22 ▼ 15% vs 2013–17
- Citations
- 228 10.4 per fractional work
- Top-10% rate
- 32.9% record average 16.5%
- Open access
- 30% world 28%
Not ranked overall: EyePoint Pharmaceuticals (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which keywords describe research at EyePoint Pharmaceuticals (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Alzheimer's Disease, Intravitreal Injection, Macular Degeneration, Oxidative Stress, Glaucoma, Vascular Endothelial Growth Factor, Neurodegenerative Diseases and Pharmacology.
- Self-Reconfiguration
- Phononic Crystals
- Acoustic Metamaterials
- Chitosan
- Optical Coherence Tomography
- Behçet's Disease
- Neuronal Signaling
- Retinal Pigment Epithelium
- Choroidal Thickness
- Cholinesterase Inhibitors
- Pharmacology
- Inflammation
- Glaucoma
- Intravitreal Injection
- Epidemiology
- Alzheimer's Disease
- Oxidative Stress
- Macular Degeneration
- Vascular Endothelial Growth Factor
- Neurodegenerative Diseases
- Acetylcholinesterase
- Diabetic Retinopathy
- Immunosuppressive Therapy
- Crystal Structure
- Nicotinic Acetylcholine Receptors
- Neurodegeneration
- Uveitis
- Nanoparticles
- Modular Robots
- Retinal Ganglion Cells
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 30 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 30 words, with their numbers
- Alzheimer's Disease4▲ 58×4 topics
- Epidemiology2▲ 2.9×4 topics
- Oxidative Stress2▲ 5.7×4 topics
- Intravitreal Injection2▲ 138×2 topics
- Macular Degeneration2▲ 75×3 topics
- Glaucoma2▲ 53×4 topics
- Vascular Endothelial Growth Factor2▲ 84×3 topics
- Inflammation2▲ 3.4×4 topics
- Neurodegenerative Diseases2▲ 39×2 topics
- Pharmacology2▲ 26×2 topics
- Acetylcholinesterase2▲ 269×1 topic
- Cholinesterase Inhibitors2▲ 269×1 topic
- Diabetic Retinopathy2▲ 90×2 topics
- Choroidal Thickness2▲ 146×1 topic
- Immunosuppressive Therapy2▲ 37×2 topics
- Retinal Pigment Epithelium2▲ 146×1 topic
- Crystal Structure2▲ 28×2 topics
- Neuronal Signaling1▲ 222×1 topic
- Nicotinic Acetylcholine Receptors1▲ 222×1 topic
- Behçet's Disease1▲ 204×1 topic
- Neurodegeneration1▲ 17×2 topics
- Optical Coherence Tomography1▲ 49×2 topics
- Uveitis1▲ 204×1 topic
- Chitosan1▲ 89×1 topic
- Nanoparticles1▲ 3.8×1 topic
- Acoustic Metamaterials1▲ 119×1 topic
- Modular Robots1▲ 132×1 topic
- Phononic Crystals1▲ 119×1 topic
- Retinal Ganglion Cells1▲ 34×2 topics
- Self-Reconfiguration1▲ 132×1 topic
Which research topics does EyePoint Pharmaceuticals (United States) publish most on?
By volume in 2022–2025: Retinal Diseases and Treatments, Lymphoma Diagnosis and Treatment, Cancer Cells and Metastasis and Angiogenesis and VEGF in Cancer.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Retinal Diseases and Treatments Ophthalmology 0 works
- 2 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
- 3 Cancer Cells and Metastasis Oncology 0 works
- 4 Angiogenesis and VEGF in Cancer Molecular Biology 0 works
- 5 Glaucoma and retinal disorders Ophthalmology 0 works
- 6 Polymer Synthesis and Characterization Polymers and Plastics 0 works
- 7 Ocular Diseases and Behçet’s Syndrome Ophthalmology 0 works
- 8 Cancer Immunotherapy and Biomarkers Oncology 0 works
- 9 Histone Deacetylase Inhibitors Research Molecular Biology 0 works
- 10 Complement system in diseases Immunology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has EyePoint Pharmaceuticals (United States)'s research output changed?
Output in 2018–2022 was 15% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Watertown
- Boston Biomedical Research Institute
- Primary Source
- Cambridge Scientific (United States)
- Radiation Monitoring Devices (United States)
- Arsenal Medical (United States)
- Pathfinder International
- New England Research Institutes
- Perkins School for Blind
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.